@BaimInstitute profile picture
Baim Institute @BaimInstitute

Baim Institute for Clinical Research is a leading, not-for-profit ARO that delivers insight, innovation and leadership in today's dynamic research environment

Joined September 2009
  • Tweets 1,873
  • Following 852
  • Followers 1,338
307 Photos and videos
Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study. doi.org/10.1161/circulationa… Contributions from Baim faculty, @f2harrell and @rallamee. #BaimInstitute #ClinicalResearch

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized,...

BACKGROUND: In stable coronary artery disease, the primary goal of percutaneous coronary intervention (PCI) is symptom relief. Fractional flow reserve (FFR) and nonhyperemic pressure ratios such as...

ahajournals.org
3
4
846
Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF. doi.org/10.1016/j.jchf.2026.… Contributions from Baim faculty, @lamcardio and @scottsolomon. #BaimInstitute #ClinicalResearch
1
1
73
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches: JACC: Heart Failure Position Statement. doi.org/10.1016/j.jchf.2026.… Contributions from Baim faculty, @lamcardio and @NMHheartdoc. #BaimInstitute
1
2
56
Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis. doi.org/10.1016/j.jacc.2026.… Contributions from Baim faculty, @lamcardio and @scottdsolomon. #BaimInstitute #ClinicalResearch
2
56
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome. doi.org/10.1016/j.jacc.2026.… Contributions from Baim faculty, @RangaswJ and @KatherineTuttl8. #BaimInstitute
2
74
Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model. doi.org/10.1093/eurheartj/eh… Contributions from Baim faculty, @ProfKausikRay and @gabrielsteg. #BaimInstitute

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with...

AbstractBackground and Aims. The 2021 ESC guidelines on cardiovascular (CV) disease prevention recommend the SMART-REACH lifetime risk model to guide treat

academic.oup.com
3
97
Baim Institute retweeted
C. Michael Gibson MD
@CMichaelGibson
Jun 12
Join us on Monday, June 29, 2026, from 9:30-10:30 am for Baim Grand Rounds with @NMHheartdoc, presenting “Health Equity: Current Status and Future Approaches.” Zoom link: us06web.zoom.us/j/8189581794…
1
4
20
1,170
Baim Institute retweeted
C. Michael Gibson MD
@CMichaelGibson
Jun 12
Reminder! Please join us on Monday, June 15, 2026, from 12-1 pm for Baim Grand Rounds with @KatherineTuttl8, presenting “GLP-1 Receptor Agonists and the "K" in Cardiovascular-Kidney-Metabolic Syndrome." Zoom Link: us06web.zoom.us/j/8565322727…
8
18
1,119
Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction: From Institutional Recognition to Clinical Integration. doi.org/10.1016/j.jchf.2026.… Contributions from Baim faculty, @lamcardio and @JavedButler1. #BaimInstitute #ClinicalResearch
1
2
168
Standardized End Point Definitions for Clinical Trials in Thoracic Aortic Repair: A Consensus Report From the ARCH-Academic Research Consortium. doi.org/10.1161/circulationa… Contributions from Baim CMO, @DonaldCutlip. #BaimInstitute #ClinicalResearch #Cardiology

Standardized End Point Definitions for Clinical Trials in Thoracic Aortic Repair: A Consensus...

Innovation in the treatment of ascending aorta and arch pathology with novel catheter-based and hybrid procedures has driven the need for a strategy to guide their safe application. The ARCH-ARC...

ahajournals.org
73
Guiding Preventive Care Strategies for Patients With Atherosclerotic Plaque on Coronary CTA: Primary Outcomes of the DECIDE Registry. doi.org/10.1016/j.jcmg.2026.… Contributions from Baim CSO, Dr. James Januzzi and Baim faculty, @CianPMcCarthy. #BaimInstitute #ClinicalResearch
1
56
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients. doi.org/10.1016/j.amjcard.20… Contributions from Baim CSO, Dr. James Januzzi. #BaimInstitute #ClinicalResearch
43
Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors by Ejection Fraction and Drug Pricing in the United States: A Systematic Review. doi.org/10.1161/circoutcomes… Contributions from Baim CSO, Dr. James Januzzi.

Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprily...

BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors and angiotensin receptor-neprilysin inhibitors (ARNI) are heart failure (HF) therapies selected for price negotiations under the...

ahajournals.org
34
FLOWing Toward Holistic Care: Heart-Kidney-Metabolic Health Re-Imagined. doi.org/10.1016/j.jacc.2026.… Contributions from Baim faculty, @RangaswJ and Baim CSO, Dr. James Januzzi. #BaimInstitute #ClinicalResearch
1
1
87
CETP Inhibitors: Back With a New Target. doi.org/10.1161/circresaha.1… Contributions from Baim faculty, Prof. Stephen Nicholls and @ProfKausikRay #BaimInstitute #ClinicalResearch

CETP Inhibitors: Back With a New Target | Circulation Research

CETP (cholesteryl ester transfer protein) plays an important role in lipid metabolism, facilitating the exchange of esterified cholesterol for triglycerides between lipoproteins. Genetic and cohort...

ahajournals.org
41
Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials. doi.org/10.1161/circulationa… Contributions from Baim faculty, @TheMahaf and @gabrielsteg. #BaimInstitute #ClinicalResearch

Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across...

BACKGROUND: Clinical end point classification (CEC) is the gold standard for cardiovascular end point measurement in clinical trials but adds time and cost. We developed and validated an artificial...

ahajournals.org
42
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses. doi.org/10.1016/j.jacc.2026.… Contributions from Baim faculty, @KatherineTuttl8 and @TheMahaf. #BaimInstitute #ClinicalResearch
1
3
102
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. doi.org/10.1001/jama.2026.99… Contributions from Baim faculty, @KatherineTuttl8 and @lamcardio. #BaimInstitute #ClinicalResearch

Finerenone for CKD Due to Glomerular Diseases

This exploratory analysis of a randomized clinical trial evaluates the efficacy and safety of finerenone in reducing chronic kidney disease of participants with glomerular diseases, including disease...

jamanetwork.com
3
4
219
Finerenone in Persons with Chronic Kidney Disease without Diabetes. doi.org/10.1056/nejmoa260462… Contributions from Baim faculty, @KatherineTuttl8 and @lamcardio. #BaimInstitute #ClinicalResearch

Finerenone in Persons with Chronic Kidney Disease without Diabetes | NEJM

In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD)...

nejm.org
2
2
129
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). doi.org/10.1016/s0140-6736(2… Contributions from Baim faculty, @KatherineTuttl8 and @lamcardio. #BaimInstitute #ClinicalResearch #CKD
1
1
66
Load more